Engineering TIL to Thrive in Hard-to-Treat Solid Tumors Using CRISPR/Cas9 Gene Editing

Time: 1:00 pm
day: Post-Conference Day - Tackling Solid Tumors

Details:

  • Harnessing the advantages of polyclonal TIL products to elicit anti-tumor responses
  • Rational design of engineered TIL, or eTIL, boosts anti-tumor potency and persistence
  • eTIL may improve the overall patient experience with TIL therapy

Speakers: